Adult patients – Page 12 – Communicable Diseases Research

Thyroid Function Before, During, and After COVID-19

코로나19 전, 중, 후 갑상선 기능

Observational Study

Published on 2020-11-122022-08-13
Journal: The Journal of Clinical Endocrinology and Metaboli [Category] Biochemistry, MERS, 임상,

Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19

급성신장손상 및 코로나19로 입원한 환자의 특징 및 결과

Research Article

Published on 2020-11-032022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS,

[키워드] Acute kidney injury Admission Adult patients AKI association baseline characteristics Biochemistry Comorbidities COVID-19 Critical care death Deprivation Deterioration diagnosis of COVID-19 disease Escalation foundation hospital hospitalised patient Initially laboratory data mechanical ventilation medications Mortality multiple organ involvement observations outcome overall mortality P-value pandemic Patient patients patients with AKI patients with COVID-19 presenting Prevent Record renal renal disease renal function renal replacement therapy replacement therapy required respiratory Result retrospective retrospective review risk shown Spread the disease Trust university with COVID-19 World Health Organisation
[DOI] 10.1371/journal.pone.0241544 PMC 바로가기 [Article Type] Research Article

Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19

혈관신생, 유전성 출혈성 모세혈관확장증 및 COVID-19

Case Reports

Published on 2020-10-142022-09-10
Journal: Angiogenesis [Category] 변종, 임상,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus-2 ACVRL1 Adult patients Angiogenesis characterized Clinical course Clinical data coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 patient COVID-19 pneumonia discharged disease endothelial damage endothelial injury Epistaxis Evidence Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia investigator mechanical ventilation multicenter open pathogenic pathogenic variant pathologic Patient patients Pneumonia Prevalence provoke rare disease rare diseases registry respiratory SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) telangiectasia Vascular worsening
[DOI] 10.1007/s10456-020-09755-5 PMC 바로가기 [Article Type] Case Reports

Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip

손끝에서 채취한 모세혈관 전혈 검체에 대한 2개의 SARS-CoV-2 Rapid IgM-IgG 결합 항체 검사의 성능 평가

Research Article

Published on 2020-09-172022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] (COronaVIrus Disease 2019) acute respiratory syndrome coronavirus 2 Adult patients Antibody test calculated capillary Chain Reaction collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic detect diagnostic different time point different time points evaluate False positive Finger prick fingertip France gold gold standard greater hospital IgG and IgM Infectious disease Nasopharyngeal swab nasopharyngeal swab specimen Nasopharyngeal swab specimens observational study occurred onset of symptom Orléans Patient patients POC POC test POC tests point-of-care polymerase chain polymerase chain reaction polymerase chain reaction) positive prospective observational study ranged Rapid Rapid test rapid test kit Rapid tests real-time reverse transcriptase resource respiratory Respiratory disease respiratory syndrome coronavirus 2 responsible Result reverse transcriptase Reverse transcriptase polymerase chain reaction RT-PCR RT-PCR testing SARS-CoV-2 SARS-CoV-2 virus sensitivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies specificity Symptom symptoms of COVID-19 tested the disease was performed Whole blood whole blood sample
[DOI] 10.1371/journal.pone.0237694 PMC 바로가기 [Article Type] Research Article

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

인공호흡기를 사용하는 COVID-19 환자에서 위약과 비교하여 72시간 동안 1ng/kg/min 용량의 프로스타사이클린(일로프로스트) 주입 효과: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] (Iloprost (normal saline) 1:1 Acute coronary syndrome Adult patient Adult patients age anticipated Biomarker bleeding blinded Blinding block can not Capital Capital Region capture Clinicians comparator concealed conducted Confirmed Confirmed COVID-19 infection Consent coronary syndrome COVID-19 COVID-19 infection COVID-19 patients criteria Day defined Denmark dissemination dose element endothelial endotheliopathy EudraCT exclusion criteria exploratory facilitate FIVE heart failure Hvidovre Hospital hypersensitivity Iloprost intensive care unit intensive care units investigators Local mechanical ventilation mechanically ventilated mechanically ventilated COVID-19 patients mechanically ventilated patient multicenter normal saline number objective outcome parallel group participant Patient patients performed Placebo Pregnancy primary endpoint prostacyclin protocol randomisation randomised Randomized Randomized controlled trial recruitment REDCap Region Sample size sequence statisticians status stratified Study protocol Suspected thrombomodulin total sample size Trial Urine website Withdrawal
[DOI] 10.1186/s13063-020-04696-2 PMC 바로가기 [Article Type] Letter

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

중환자실에 입원한 COVID-19 환자의 정맥 주사 멜라토닌의 효능과 안전성을 조사하기 위한 2상, 단일 센터, 이중 맹검, 무작위 위약 대조 시험(MelCOVID 연구): 연구 프로토콜의 구조화된 요약 무작위 대조 시험을 위해

Letter

Published on 2020-08-052022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 6 hours Acute hypoxemic respiratory failure addition Admission Adult patients adverse effect adverse event adverse events age allocation anticipated Autoimmune disease Biochemical parameters blinded Blinding blood gas blood gas analysis body weight C-reactive protein Caregivers carried chronic Chronic kidney disease clinical condition clinical development commercialization comparator compatible symptom compatible symptoms Complete completion computer conducted Confirmed Consent Control control arm control group COVID-19 COVID-19-associated thromboembolic phenomena Critically ill D-dimer daily dose Date determined by disease dissemination double-blind Efficacy and safety element enzyme EU Clinical Trial evaluate evaluate the effect exclusion criteria expected experimental arm experimental group failing organ failing organs family member ferritin Frequency gas analysis GFR greater hematologic Hemodialysis hypoxemic Hypoxemic respiratory failure ICU ICU admission impairment Inclusion inclusion criteria increase in inflammatory state Informed institutional protocols intensive care intensive care unit interleukin interleukin-6 intravenous Kidney disease legal guardian less liver enzymes maximum mechanical ventilation medical illness melatonin Mortality multi-organ failure normal range number objective Organ failure outcome parameters participant Patient patient condition patients with COVID-19 per day performed phase physician Placebo placebo-controlled randomized trial plasma Plasma levels positive RT-PCR Pregnancy pregnancy test Prevent procalcitonin Program protocol provided randomization randomization sequence Randomized Randomized controlled trial randomized placebo-controlled trial receive recruited recruitment reduced reduction Respiratory failure Sample size SARS-COV-2 infection SAS version 9.4 SAS version 9.4 statistical software secondary Secondary objectives Sequential Organ Failure Assessment severity single center single-center SOFA Spain Stage Standard-of-care statistical status study drug study group study groups study period Study protocol systemic inflammatory response Terminal surgical thromboembolic Treatment Trial Trial registration two-arm parallel Ventilator-free days website with COVID-19 worsening written Informed Consent
[DOI] 10.1186/s13063-020-04632-4 PMC 바로가기 [Article Type] Letter

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

AGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판

Letter

Published on 2020-06-192022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 9-point ordinal scale acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive added Adult patients Adverse adverse events agent Anti-viral treatment approval Bayesian Blinding candidate Candidates clinical Clinical improvement cloud Cohort cohorts Combination Common Terminology Criteria Community community setting comparator contributing to coronavirus COVID-19 COVID-19 infection CST cytokine cytokine release death defined determine disease dissemination dose EDC Efficacy Efficacy and safety element eligibility criteria eligible England EudraCT evaluated expected for inclusion futility GRADE group hospitalised hospitalised patient Hospitalization in some include Infection intubation Ireland laboratory-confirmed later phase limit Mask Master protocol mechanical ventilation mechanism mechanism of action multi-arm multicentre Multiple nasal prongs non-invasive ventilation North number objective open Open-label opens optimal dose Ordinal Scale organ Other outcome oxygen oxygen saturation oxygen) participant Patient patient population patients peripheral capillary Peripheral capillary oxygen saturation phase Phase I/II Placebo platform Platform study Platform trial Population Prevent progression of disease promise protocol randomisation randomised Rave recruited recruitment Regulatory required respiratory Safety Sample size SARS-CoV-2 SARS-COV-2 infection seamless setup severe acute respiratory syndrome Coronavirus severe disease shown SOC Specific Stage Standard Standard of care status Study protocol the WHO toxicities Toxicity Treatment treatment of COVID-19 Trial Trial registration Ventilation Viral Viral load viral replication website WHO working
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial

중증 COVID-19 성인 환자에 대한 정맥 주사 렘데시비르의 효능 및 안전성 평가: 무작위 배정, 이중 맹검, 위약 대조, 다기관 임상 3상 연구 프로토콜

Study Protocol

Published on 2020-05-242022-09-10
Journal: Trials [Category] MERS, SARS, 비임상,

[키워드] Administered Administrative information Adult patients Antiviral assigned asymptomatic infection breath category caused China Clinical efficacy Clinical improvement clinical manifestation clinical manifestations clinical status clinical trial concern conducted coronavirus disease Coronavirus disease 2019 Coronavirus infections Coronaviruses COVID-19 COVID-19 virus death defined discharge double-blind Efficacy Efficacy and safety Emergency enrolment event futility GS-5734 Health Organization highly pathogenic hospital in vitro in vivo experiments include Infection inhibitory inhibitory effect Inhibitory effects interim analysis Intravenous remdesivir intravenously laboratory-confirmed MERS-CoV Mild multicentre nucleoside Ordinal Scale Patient Phase 3 Placebo placebo-controlled placebo-controlled trial Pneumonia primary endpoint protocol Public public health emergency randomization Randomized Randomly Remdesivir reported required Respiratory failure SARS-CoV SARS-CoV-2 virus severe COVID-19 severe pneumonia severe viral pneumonia Spread Standard Study protocol Symptoms Treatment Trial Trial registration upper respiratory symptoms Viral Viral pneumonia virus infection World Health Organization Wuhan
[DOI] 10.1186/s13063-020-04352-9 PMC 바로가기 [Article Type] Study Protocol

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

중증 COVID-19 성인에 대한 렘데시비르: 무작위, 이중 맹검, 위약 대조, 다기관 시험

Randomized Controlled Trial

Published on 2020-05-162022-09-11
Journal: Lancet (London, England) [Category] SARS, 비임상,

[키워드] Academy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adult patients Adverse adverse event adverse events Analysis animal models antiviral drug arterial oxygen partial pressure assigned Beijing breath China Chinese clinical benefits Clinical improvement clinical status concomitant use confirmation coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 defined development discharged double-blind effective Eligible patients Emergency enrolled enrolment event faster followed by fractional inspired oxygen GS-5734 hazard ratio hospital human coronaviruses in vitro inhibit inhibitory effect Inhibitory effects intention-to-treat interferons Intravenous remdesivir ITT ITT population laboratory-confirmed SARS-CoV-2 infection less Lopinavir Lopinavir-ritonavir Medical Science Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus multicentre nucleoside one patient Ordinal Scale oxygen oxygen partial pressure oxygen saturation partial pressure pathogenic Patient Placebo placebo group placebo recipients placebo-controlled Pneumonia primary analysis primary endpoint Program randomisation randomised Randomly receiving recipient reduction in Registered Remdesivir reported research and development respiratory respiratory syndrome coronavirus Ritonavir room air safety analysis SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Science severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 statistically significant symptom duration symptom onset technology the placebo group those receiving placebo treated Treatment treatment group Trial Volume was done
[DOI] 10.1016/S0140-6736(20)31022-9 PMC 바로가기 [Article Type] Randomized Controlled Trial